Arvinas, Pfizer reworking partnership on ‘Protac’ cancer drug
Written by
BioPharma Dive
Published
0
comments
0
min
The smaller market now envisioned for vepdegestrant has changed both companies’ stance on their original deal, leading to negotiations that could either lead to a new alliance or Arvinas to seek a new partner.